Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non‐small cell lung cancer: Updated follow‐up results from two phase II trials

Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non‐small cell lung cancer: Updated follow‐up results from two phase II trials

Background There are two main choices of administration route of recombinant human endostatin (Endostar) available and the treatment options of concurrent chemoradiotherapy (CCRT) have changed over time. The aim of this study was to observe the long‐term efficacy and safety of different administrati...

Full description

Bibliographic Details
Main Authors: Ma Honglian, Hui Zhouguang, PENG Fang, Zhao Lujun, Li Dongming, Xu Yujin, Bao Yong, Xu Liming, Zhai Yirui, Hu Xiao, Wang Jin, Kong Yue, Wang Lvhua, Chen Ming
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Thoracic Cancer
Subjects:
Concurrent chemoradiotherapy
continuous intravenous pumping
intravenous injection
non‐small cell lung cancer
recombinant human endostatin
Online Access:https://doi.org/10.1111/1759-7714.13333

Internet

https://doi.org/10.1111/1759-7714.13333

Similar Items